Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.

Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J.

Arthritis Rheumatol. 2020 Jan;72(1):150-156. doi: 10.1002/art.41063. Epub 2019 Dec 10.

PMID:
31353871
2.

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase.

Keenan RT, Baraf HSB, LaMoreaux B.

Rheumatol Ther. 2019 Jun;6(2):299-304. doi: 10.1007/s40744-019-0151-9. Epub 2019 Mar 14.

3.
4.

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.

Bray VJ, Broadwell A, Baraf HSB, Black S, Brady BL, Tkacz J, Yarngo L, DeHoratius RJ.

Drugs R D. 2018 Sep;18(3):211-219. doi: 10.1007/s40268-018-0240-1.

5.

Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA.

J Clin Rheumatol. 2014 Dec;20(8):427-32. doi: 10.1097/RHU.0000000000000200. Review.

6.

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA.

Arthritis Res Ther. 2013 Sep 26;15(5):R137. doi: 10.1186/ar4318.

7.

Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.

Dalbeth N, Doyle AJ, McQueen FM, Sundy J, Baraf HS.

Arthritis Care Res (Hoboken). 2014 Jan;66(1):82-5. doi: 10.1002/acr.22059.

8.

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP.

Arthritis Res Ther. 2013 Feb 1;15(1):R25. doi: 10.1186/ar4159.

9.

Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).

Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A.

Clin Exp Rheumatol. 2013 May-Jun;31(3):358-64. Epub 2013 Jan 10.

PMID:
23305631
10.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

11.

Effectiveness and Safety of a Multicenter Extension and Retreatment Trial of Gel-200 in Patients with Knee Osteoarthritis.

Strand V, Baraf HS, Lavin PT, Lim S, Hosokawa H.

Cartilage. 2012 Oct;3(4):297-304. doi: 10.1177/1947603512451024.

12.
13.

2011 recommendations for the diagnosis and management of gout and hyperuricemia.

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL.

Phys Sportsmed. 2011 Nov;39(4):98-123. doi: 10.3810/psm.2011.11.1946. Review.

PMID:
22293773
14.

Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities.

Baraf HS, Gold MS, Petruschke RA, Wieman MS.

Am J Geriatr Pharmacother. 2012 Feb;10(1):47-60. doi: 10.1016/j.amjopharm.2011.12.002. Epub 2012 Jan 20.

PMID:
22264852
15.

2011 Recommendations for the diagnosis and management of gout and hyperuricemia.

Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, Doghramji PP, Guadagnoli GA, Hamburger F, Harford R, Lieberman JA 3rd, Mandel DR, Mandelbrot DA, McClain BP, Mizuno E, Morton AH, Mount DB, Pope RS, Rosenthal KG, Setoodeh K, Skosey JL, Edwards NL; European League Against Rheumatism.

Postgrad Med. 2011 Nov;123(6 Suppl 1):3-36. doi: 10.3810/pgm.2011.11.2511.

PMID:
22156509
16.

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA.

JAMA. 2011 Aug 17;306(7):711-20. doi: 10.1001/jama.2011.1169.

PMID:
21846852
17.
18.

Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial.

Baraf HS, Gold MS, Clark MB, Altman RD.

Phys Sportsmed. 2010 Jun;38(2):19-28. doi: 10.3810/psm.2010.06.1779.

PMID:
20631460
19.

Resolution of gouty tophi after twelve weeks of pegloticase treatment.

Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW 2nd.

Arthritis Rheum. 2008 Nov;58(11):3632-4. doi: 10.1002/art.23993. No abstract available.

20.

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators.

Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810.

21.

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.

Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG.

Ann Rheum Dis. 2008 Jun;67(6):888-91. Epub 2007 Nov 29. Erratum in: Ann Rheum Dis. 2008 Nov;67(11):1652.. Mellado, J Vazquez [corrected to Vazquez-Mellado, J].

PMID:
18055475
22.

Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.

Baraf HS.

Curr Pharm Des. 2007;13(22):2228-36. Review.

PMID:
17691996
23.

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP; EDGE Study Group.

J Rheumatol. 2007 Feb;34(2):408-20.

PMID:
17304660
24.

Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.

van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, James M, Markind JE, Reicin AS, Melian A, Dougados M.

Arthritis Rheum. 2005 Apr;52(4):1205-15.

25.

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.

Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon ME, Moidel RA, Green JA, Baraf HS, Petruschke RA, Matsumoto AK, Geba GP; Protocol 085 Study Investigators.

J Am Geriatr Soc. 2004 May;52(5):666-74.

PMID:
15086644
26.

Systemic sclerosis and pregnancy complicated by obstructive uropathy.

Moore M, Saffran JE, Baraf HS, Jacobs RP.

Am J Obstet Gynecol. 1985 Dec 15;153(8):893-4.

PMID:
2933959
27.

Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout.

Reynolds PP, Knapp MJ, Baraf HS, Holmes EW.

Arthritis Rheum. 1983 Sep;26(9):1057-64. No abstract available.

PMID:
6412722

Supplemental Content

Loading ...
Support Center